Strategic merger Leverage the history of Keryx and Akebia integration to position products for chronic kidney disease (CKD) care teams, emphasizing continuity of care and expanded resource access through the merged entity.

Product portfolio Focus on Auryxia and Zerenex opportunities related to hyperphosphatemia and ESRD, targeting nephrology clinics, dialysis centers, and CKD patient management programs seeking iron-based phosphate binders and anemia therapies.

FDA milestones Capitalize on past FDA approvals for Auryxia and ongoing development of Zerenex to approach payer and procurement decision-makers with evidence of novel CKD-related therapies and potential clinical benefits.

Geographic footprint Target the U.S. market where the company has historically launched CKD therapies, aligning with hospital networks, IV iron therapies, and renal care programs that manage mineral bone disorder and iron deficiency in CKD.

Collaborations & networks Engage NKF and other nephrology patient organizations as potential channels for awareness, education, and access programs, while exploring partnerships with specialty pharmacies and dialysis providers to expand distribution.